http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Merck launches tender offer to acquire Terns Pharmaceuticals for $53 per share
-
Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
-
Merck starts phase 2b/3 trial for eye disease drug MK-8748
-
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular
-
European Commission approves KEYTRUDA plus paclitaxel for ovarian cancer
-
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Receive
-
Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30
-
Merck drug shows superior cholesterol reduction in phase 3 trial
-
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies
-
Merck's WINREVAIR shows promise in heart failure trial
-
Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension
-
Merck to acquire Terns Pharmaceuticals for $6.7 billion
-
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
-
FDA expands BRAVECTO QUANTUM label to cover two additional tick species
-
FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs
-
Merck to present HPV vaccine data showing 14-18 year efficacy
-
Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026
-
Merck to present data on cholesterol and heart failure drugs at ACC.26
-
Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research
-
KEYTRUDA Plus WELIREG Shows 28% Reduction in Cancer Recurrence Risk
-
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlie
-
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carc
-
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients
-
Merck's KEYTRUDA plus Padcev reduces bladder cancer risk in trial
-
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladd
-
FDA approves Merck's NUMELVI for dog skin allergies
-
FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Alle
-
Merck shares data on two-drug HIV regimen at medical conference
-
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1
-
Merck to Participate in the TD Cowen 46th Annual Health Care Conference
-
Merck restructures human health division into two business units
-
Merck Evolves Human Health Operating Structure to Support Portfolio Execution
-
Merck reports positive second-season data for RSV drug in high-risk children
-
Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seaso
-
Merck and Mayo Clinic partner on AI drug discovery collaboration
-
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine
-
Merck presents cancer treatment data at ASCO GU symposium
-
Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium
-
FDA approves Merck's KEYTRUDA and KEYTRUDA QLEX for ovarian cancer
-
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant O
-
Merck Announces Second-Quarter 2026 Dividend
-
Merck starts phase 3 trial of KRAS G12C inhibitor with KEYTRUDA QLEX
-
Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa
-
Merck to Complete Acquisition of Cidara Therapeutics
-
Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3
-
Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference
-
Merck agrees with US government to expand medicine access and cut costs
-
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
-
Merck reports positive results for KEYTRUDA plus Padcev in bladder cancer
-
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients w
